Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novavax Inc (NVAX) vs Snap On Incorporated (SNA) Price & Performance

Novavax IncTrade
Snap On IncorporatedTrade

Price performance (Past 24H)

Key statistics

Novavax Inc vs Snap On Incorporated — how do they compare? Novavax Inc trades at $7.97 (market cap $1.31B), while Snap On Incorporated trades at $408.11 (market cap $21.30B). The key difference: Snap On Incorporated is far larger — about 16.3× Novavax Inc's market cap, and Snap On Incorporated pays a 2.37% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

NVAXSNA
Market Cap
$1.31B$21.30B
Sector
HealthTechnology
52-Week High
$11.19$419.31
52-Week Low
$6.22$321.38
Enterprise Value
$889.30M$20.93B
Dividend Yield
2.37%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novavax Inc

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.

Snap On Incorporated

Snap-on Incorporated (SNA) trades at $408.44, down 0.65% with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 19.6% net income margin and 17.58% ROE, though valuation metrics appear elevated. Recent Q2 2026 earnings beat expectations with $4.96 EPS, while the $100 million Diesel Laptops acquisition expands diagnostics capabilities.

SNA offers steady growth potential with strong cash flow generation and consistent dividends, but faces integration risks from recent acquisitions and premium valuation concerns. Analyst consensus remains bullish with $455.33 price target, though execution on growth initiatives will be critical for sustaining momentum amid competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX

About Snap On Incorporated

Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.

Read more on SNA